Mind Medicine Inc (MNMD)

May 09, 2025

Mind Medicine (MNMD) Rating and Price Target Maintained by Chard - GuruFocus

May 09, 2025

May 09, 2025

Psychedelic: Compass, GH Research, MindMed report quarterly earnings - Yahoo Finance

May 09, 2025

May 09, 2025

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance - insights.citeline.com

May 09, 2025

May 09, 2025

Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial ... - Yahoo Finance

May 09, 2025

May 09, 2025

Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - GuruFocus

May 09, 2025

May 09, 2025

MindMed Advances Phase 3 Trials for Brain Health - TipRanks

May 09, 2025

May 08, 2025

Transcript : Mind Medicine Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com

May 08, 2025

May 08, 2025

MindMed Advances Phase 3 Trials for Brain Health Treatments - TipRanks

May 08, 2025

May 08, 2025

MindMed Q1 2025 slides: Phase 3 trials advance as cash position remains strong - Investing.com Australia

May 08, 2025

May 08, 2025

Earnings call transcript: MindMed Q1 2025 results show mixed signals By Investing.com - Investing.com UK

May 08, 2025

May 08, 2025

MindMed (MNMD) Advances Phase 3 Trials with Growing Enthusiasm | MNMD Stock News - GuruFocus

May 08, 2025

May 08, 2025

Mind Medicine (MindMed) Inc. SEC 10-Q Report - TradingView

May 08, 2025

May 08, 2025

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates - The Joplin Globe

May 08, 2025

May 06, 2025

(MNMD) Long Term Investment Analysis - news.stocktradersdaily.com

May 06, 2025

May 01, 2025

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 | MNMD Stock News - GuruFocus

May 01, 2025

Apr 24, 2025

Great week for Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) institutional investors after losing 28% over the previous year - simplywall.st

Apr 24, 2025

Apr 24, 2025

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 - Business Wire

Apr 24, 2025

Apr 23, 2025

Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence - Seeking Alpha

Apr 23, 2025

Apr 23, 2025

Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Yahoo Finance

Apr 23, 2025

Apr 21, 2025

Mind Medicine (Mindmed) IncMindmed Enters Into First Amendment To Loan And Security AgreementSEC Filing - marketscreener.com

Apr 21, 2025

Apr 21, 2025

MindMed Announces New Employee Inducement Grants | MNMD Stock Ne - GuruFocus

Apr 21, 2025

Apr 21, 2025

MindMed Announces New Employee Inducement Grants | MNMD Stock News - GuruFocus

Apr 21, 2025

Apr 21, 2025

MindMed Announces New Employee Inducement Grants - Business Wire

Apr 21, 2025

Apr 21, 2025

Lobbying Update: $100,000 of MIND MEDICINE (MINDMED) INC. lobbying was just disclosed - Nasdaq

Apr 21, 2025

Apr 20, 2025

Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges (NASDAQ:MNMD) - Seeking Alpha

Apr 20, 2025

Apr 20, 2025

How the (MNMD) price action is used to our Advantage - news.stocktradersdaily.com

Apr 20, 2025

Apr 16, 2025

Broadway Gold Mining : MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations - marketscreener.com

Apr 16, 2025

Apr 16, 2025

MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder - TipRanks

Apr 16, 2025

Apr 16, 2025

Oppenheimer maintains MindMed stock Outperform with $20 target By Investing.com - Investing.com India

Apr 16, 2025

Apr 15, 2025

MindMed launches phase 3 LSD study for depression By Investing.com - Investing.com Nigeria

Apr 15, 2025

Apr 15, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - GuruFocus

Apr 15, 2025

Apr 15, 2025

MindMed launches phase 3 LSD study for depression - Investing.com Australia

Apr 15, 2025

Apr 15, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of - GuruFocus

Apr 15, 2025

Apr 15, 2025

Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd) - marketscreener.com

Apr 15, 2025

Apr 07, 2025

MindMed Appoints Schond L. Greenway as Chief Financial Officer - MarketScreener

Apr 07, 2025

Apr 04, 2025

MNMD stock touches 52-week low at $5.03 amid market challenges - Investing.com India

Apr 04, 2025

Apr 04, 2025

Long Term Trading Analysis for (MNMD) - news.stocktradersdaily.com

Apr 04, 2025

Apr 04, 2025

MNMD stock touches 52-week low at $5.03 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Mar 30, 2025

MNMD Stock Forecast From 2025 To 2040 - Exla Resources

Mar 30, 2025

Mar 27, 2025

Mind Medicine CEO Robert Barrow sells shares worth $142,941 By Investing.com - Investing.com India

Mar 27, 2025

Mar 26, 2025

MindMed Advances Clinical Programs with Strong Financial Backing - TipRanks

Mar 26, 2025

Mar 26, 2025

Mind Medicine CEO Robert Barrow sells shares worth $142,941 - Investing.com

Mar 26, 2025

Mar 24, 2025

MindMed Strengthens Brain Health Pipeline with Key Technical Talent Acquisition - Stock Titan

Mar 24, 2025

Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR

Mar 21, 2025

Mar 17, 2025

MindMed appoints new Chief Commercial Officer By Investing.com - Investing.com South Africa

Mar 17, 2025

Mar 17, 2025

MindMed Appoints Matt Wiley as Chief Commercial Officer - Quantisnow

Mar 17, 2025

Mar 17, 2025

MindMed appoints new Chief Commercial Officer - Investing.com

Mar 17, 2025